Risk factors and predictive value of Framingham Risk Score of young men with coronary artery disease

doi:10.3969/j.issn.1006-7795.2022.01.024

Abstract

Abstract: Objective To investigate the risk factors and predictive value of Framingham Risk Score of young men with coronary artery disease (CAD).Methods A total of 201 young male patients (30≤age<45 years old) who underwent coronary angiography in Beijing Ditan Hospital, Capital Medical University from July 2016 to July 2019 were selected as the research subjects. According to the results of coronary angiography, they were divided into two groups: CAD group (n=139) and non-CAD group (n=62). Framingham Risk Score was calculated for all patients, and patients in both groups were divided into two subgroups according to Framingham Risk Score: low risk group and high risk group/moderate risk group. The severity of coronary artery disease in patients with CAD was assessed by Gensini score, and the medical history and relevant clinical and laboratory indicators of all subjects were collected. Results The proportions of smoking, hypertension and family history of CAD in CAD group were higher than those in non-CAD group (P<0.05).There were significant differences in high density lipoprotein-cholesterol (HDL-C), ApoB/ApoA and non-HDL-C in CAD group (P<0.05). There was no statistical difference in the mean Framingham Risk Score between CAD group and non-CAD group as well as the proportion of patients in the low-risk Framingham Risk Score and the medium/high risk Framingham Risk Score. Further analysis of the correlation between the Framingham Risk Score and Ginsini Score in the CAD group showed no linear correlation (P=0.749).The area under the receiver operating characteristic (ROC) curve of the Framingham Risk Score was 0.544 (95%CI: 0.458-0.629, P =0.324).Binary linear multivariate Logistic regression analysis showed that hypertension, family history of premature coronary atery disease and homocysteine (HCY) were independent risk factors for coronary heart disease in young men,while HDL-C is a protective factor in these samples. Conclusion A single-center cross-sectional study shows that Framingham Risk Score cannot adequately assess coronary artery severity in young male patients with CAD. The importance of non-traditional CAD risk factors should be considered in young male patients with early onset CAD, and future prospective studies with more samples are needed to verify this.

Key words: young men, premature coronary artery disease, Framingham Risk Score, Gensini Score

CLC Number:

R541.4

Su Yunjuan, Wang Jingjing, Han Xiaotao, Liu Haiyan, Chen Yongfu, Yang Liu, Wu Qiming. Risk factors and predictive value of Framingham Risk Score of young men with coronary artery disease[J]. Journal of Capital Medical University, 2022, 43(1): 143-148.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.01.024

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I1/143

References

[1] Bauersachs R, Zeymer U, Brière J B, et al. Burden of coronary artery disease and peripheral artery disease: a literature review[J]. Cardiovasc Ther, 2019, 2019: 8295054.
[2] Fan F F, Li Y X, Zhang Y, et al. Chest pain center accreditation is associated with improved In-Hospital outcomes of acute myocardial infarction patients in China: findings from the CCC-ACS project[J]. J Am Heart Assoc, 2019, 8(21): e013384.
[3] Zheng W, Wang J L, Xu F, et al. Evaluation and management of patients with acute chest pain in China (EMPACT): protocol for a prospective, multicentre registry study[J]. BMJ Open, 2018, 8(1): e017872.
[4] Andersson C, Vasan R S. Epidemiology of cardiovascular disease in young individuals[J]. Nat Rev Cardiol, 2018, 15(4): 230-240.
[5] Marma A K, Lloyd-Jones D M. Systematic examination of the updated Framingham heart study general cardiovascular risk profile[J]. Circulation, 2009, 120(5): 384-390.
[6] Malakar A K, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics[J]. J Cell Physiol, 2019, 234(10): 16812-16823.
[7] Khera A V, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation[J]. Nat Rev Genet, 2017, 18(6): 331-344.
[8] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Kardiol Pol, 2018, 76(2): 229-313.
[9] Liu S W, Li Y C, Zeng X Y, et al. Burden of cardiovascular diseases in China, 1990-2016: findings from the 2016 global burden of disease study[J]. JAMA Cardiol, 2019, 4(4): 342-352.
[10] Zeitouni M, Clare R M, Chiswell K, et al. Risk factor burden and long-term prognosis of patients with premature coronary artery disease[J]. J Am Heart Assoc, 2020, 9(24): e017712.
[11] Ge J, Li J, Yu H, et al.Hypertension Is an Independent Predictor of Multivessel Coronary Artery Disease in Young Adults with Acute Coronary Syndrome[J]. Int J Hypertens,2018,2018:7623639.
[12] Christiansen M K, Jensen J M, Nørgaard B L, et al. Coronary plaque burden and adverse plaque characteristics are increased in healthy relatives of patients with early onset coronary artery disease[J]. JACC Cardiovasc Imaging, 2017, 10(10 Pt A): 1128-1135.
[13] Kaur R, Das R, Ahluwalia J, et al. Genetic polymorphisms, biochemical factors, and conventional risk factors in young and elderly north Indian patients with acute myocardial infarction[J]. Clin Appl Thromb Hemost, 2016, 22(2): 178-183.
[14] Jortveit J, Pripp A H, Langørgen J, et al. Incidence, risk factors and outcome of young patients with myocardial infarction[J]. Heart, 2020, 106(18): 1420-1426.
[15] Koller A, Szenasi A, Dornyei G, et al. Coronary microvascular and cardiac dysfunction due to homocysteine pathometabolism; a complex therapeutic design[J]. Curr Pharm Des, 2018, 24(25): 2911-2920.
[16] Jakubowski H. Homocysteine modification in protein structure/function and human disease[J]. Physiol Rev, 2019, 99(1): 555-604.
[17] Djuric D, Jakovljevic V, Zivkovic V, et al. Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems[J]. Can J Physiol Pharmacol, 2018, 96(10): 991-1003.
[18] Li T Y, Yu B, Liu Z X, et al. Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injury[J]. Nat Commun, 2018, 9(1): 11.
[19] Visram M, Radulovic M, Steiner S, et al. Homocysteine regulates fatty acid and lipid metabolism in yeast[J]. J Biol Chem, 2018, 293(15): 5544-5555.
[20] Jud P, Hafner F, Verheyen N, et al. Age-dependent effects of homocysteine and dimethylarginines on cardiovascular mortality in claudicant patients with lower extremity arterial disease[J]. Heart Vessels, 2018, 33(12): 1453-1462.
[21] Xie J C, Qi J, Mao H Y, et al. Coronary plaque tissue characterization in patients with premature coronary artery disease[J]. Int J Cardiovasc Imaging, 2020, 36(6): 1003-1011.
[22] Kaplan P, Tatarkova Z, Sivonova M K, et al. Homocysteine and mitochondria in cardiovascular and cerebrovascular systems[J]. Int J Mol Sci, 2020, 21(20): 7698.
[23] Ikram S, Pachika A, Schuster H, et al. Single-center retrospective study of risk factors and predictive value of Framingham risk score of patients with ST elevation myocardial infarction[J]. South Med J, 2018, 111(4): 226-229.